Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DMIIR vs DMAAR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAAR Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 3–0 Matrix Metrics)

DMAAR Overall Winner 6-Pillar Tally: DMIIR 0 – 0 DMAAR (6 Tie) Matrix Metrics: DMIIR 0 – 3 DMAAR

As of Nov 20, 2026, Drugs Made In America Acquisition Corp. Rights (DMAAR) is the stronger overall head-to-head candidate over DMIIR (DMIIR) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). DMIIR carries a Unified Composite Score of 33.1/100 (SELL) at $0.07 (N/M Forward P/E, N/A operating margin), whereas DMAAR carries 43.5/100 (HOLD) at $0.12 (N/M Forward P/E, N/A operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DMIIR vs DMAAR
DMIIR US Equity
DMIIR
Institutional Equity
$0.07
+7.31% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.53β · 168% Vol
Unified Composite Score
33.1 / 100 SELL
Tech 30.0 Fund 42.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $0.09 · SMA50: $0.10
DMAAR NASDAQ Head-to-Head Winner
Drugs Made In America Acquisition Corp. Rights
Blank Checks
$0.12
+0.0% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.48β · 147% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 30.0 Fund 44.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 53.0 · SMA20: $0.11 · SMA50: $0.12

6-Pillar Scorecard Institutional Category Breakdown (DMIIR 0 – 0 DMAAR)

Columns: Metric · DMIIR · DMAAR
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Blank Checks Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DMIIR (0) vs DMAAR (3)
Institutional Metric DMIIR DMAAR Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
15% ($0–$0) 43% ($0–$0) Stronger Trend DMAAR
Beta / 30D Volatility
Risk Regime
-0.53β · 168% Vol 0.48β · 147% Vol Lower Realized Risk DMAAR
Unified Institutional Score
Composite Signal
33.1 / 100 (SELL) 43.5 / 100 (HOLD) Higher Composite DMAAR
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAAR +1.55 pp
DMIIR: -3.43% · DMAAR: -1.88%
3M Horizon DMAAR +25.16 pp
DMIIR: -24.92% · DMAAR: +0.24%
6M Horizon DMAAR +18.53 pp
DMIIR: -51.79% · DMAAR: -33.26%
1Y Horizon DMAAR +20.82 pp
DMIIR: -55.0% · DMAAR: -34.18%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DMIIR vs DMAAR. Trailing 12-month operating profitability (DMIIR N/A vs DMAAR N/A) and valuation multiples (DMIIR N/M vs DMAAR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DMIIR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
DMAAR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DMIIR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DMIIR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DMAAR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DMAAR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DMIIR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DMAAR Moat Profile Cyclical / Execution-Driven Positioning
Blank Checks Operator
Competes within the Blank Checks value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DMIIR vs DMAAR Key Questions & Quantitative Answers

As of Nov 20, 2026, Drugs Made In America Acquisition Corp. Rights (DMAAR) is the stronger overall head-to-head candidate over DMIIR (DMIIR) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). DMIIR carries a Unified Composite Score of 33.1/100 (SELL) at $0.07 (N/M Forward P/E, N/A operating margin), whereas DMAAR carries 43.5/100 (HOLD) at $0.12 (N/M Forward P/E, N/A operating margin). Technically, DMIIR sits in a Neutral phase (RSI 47.4, UNCLASSIFIED options structure) and DMAAR sits in a Neutral phase (RSI 53.0, UNCLASSIFIED options structure).

DMIIR and DMAAR split Growth & Scale metrics: DMIIR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with DMAAR at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, DMIIR generates N/A in USD-normalized revenue versus N/A for DMAAR. In operating R&D and SG&A reinvestment, DMIIR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAAR.

DMIIR and DMAAR trade at balanced relative valuation multiples. DMIIR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas DMAAR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMIIR (N/A ROE) versus DMAAR (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, DMIIR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.53β · 168% Vol realized risk). By comparison, DMAAR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 147% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.